|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-9-26
|
|
pubmed:abstractText |
Patients infected with hepatitis C virus genotype 1 who are true non-responders to previous therapy suffer from a very difficult-to-cure disease. New approaches to treatment are necessary.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0269-2813
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1131-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17894655-Adult,
pubmed-meshheading:17894655-Antiviral Agents,
pubmed-meshheading:17894655-Dose-Response Relationship, Drug,
pubmed-meshheading:17894655-Drug Therapy, Combination,
pubmed-meshheading:17894655-Female,
pubmed-meshheading:17894655-Hepatitis C, Chronic,
pubmed-meshheading:17894655-Humans,
pubmed-meshheading:17894655-Interferon-alpha,
pubmed-meshheading:17894655-Male,
pubmed-meshheading:17894655-Middle Aged,
pubmed-meshheading:17894655-Polyethylene Glycols,
pubmed-meshheading:17894655-Recombinant Proteins,
pubmed-meshheading:17894655-Ribavirin,
pubmed-meshheading:17894655-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
|
|
pubmed:affiliation |
Hepatology Section, Hospital General de Valencia, Valencia, Spain.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
